Clearside Biomedical, Inc. (Nasdaq: CLSD) has been actively promoting its suprachoroidal delivery technology and pipeline programs at various medical conferences spanning Asia, Europe, and the United States. The company's presence at these events underscores its commitment to advancing novel drug delivery methods for treating sight-threatening eye diseases.
Showcasing SCS Microinjector Technology
At the 17th Asia-Pacific Vitreo-Retina Society (APVRS) Congress in Singapore, Clearside made a notable impact by presenting topline results from the ODYSSEY trial, real-world data on XIPERE, and four posters detailing their suprachoroidal delivery platform. A highlight was the hosting of three fully-attended demonstration sessions of their SCS Microinjector technology.
Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research and Development at Clearside Biomedical, noted the growing interest in their delivery approach, particularly as their partner Arctic Vision advances XIPERE towards potential approval in China, Australia, and Singapore. "We were pleased that each session reached maximum attendance capacity," he stated.
Milestone: 10,000+ Injections with SCS Microinjector
Clearside's SCS Microinjector has now been used in over 10,000 injections, marking a significant milestone in the adoption of this innovative drug delivery system. This achievement solidifies Clearside's position as a frontrunner in suprachoroidal space delivery of therapeutic agents.
ODYSSEY Trial and CLS-AX Program
The ODYSSEY Phase 2b clinical trial evaluated CLS-AX (axitinib injectable suspension) in participants with wet age-related macular degeneration (AMD) previously treated with intravitreal anti-VEGF therapy. Results from the ODYSSEY trial demonstrated compelling intervention-free rates, with a significant reduction in injection frequency compared to previous treatments. Specifically, 100% of CLS-AX participants required no additional treatment up to 3 months, 90% up to 4 months, 81% up to 5 months, and 67% up to 6 months after the initial CLS-AX dose.
Clearside is advancing CLS-AX as a longer-acting therapy for retinal diseases. Axitinib, a tyrosine kinase inhibitor (TKI), achieves pan-VEGF blockade, potentially offering efficacy advantages over existing retinal therapies. The suprachoroidal injection of axitinib aims to provide prolonged duration and targeted delivery to affected tissue layers, limiting drug exposure to the front of the eye.
Upcoming Presentations
Clearside Biomedical plans to present further data from the Phase 2b ODYSSEY trial at upcoming medical meetings. The company's CLS-AX program is now Phase 3 ready, signaling continued progress in addressing unmet needs in retinal disease treatment.
